Literature DB >> 33778580

Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry Disease: Clinical Significance of Discrepant Findings.

Ciara O'Brien1, Ian Britton1, Gauri R Karur1, Robert M Iwanochko1, Chantal F Morel1, Elsie T Nguyen1, Paaladinesh Thavendiranathan1, Anna Woo1, Kate Hanneman1.   

Abstract

PURPOSE: To compare transthoracic echocardiography (TTE) and cardiac MRI measurements of left ventricular mass (LVM) and maximum wall thickness (MWT) in patients with Fabry disease and evaluate the clinical significance of discrepancies between modalities.
MATERIALS AND METHODS: Seventy-eight patients with Fabry disease (mean age, 46 years ± 14 [standard deviation]; 63% female) who underwent TTE and cardiac MRI within a 6-month interval between 2008 and 2018 were included in this retrospective cohort study. The clinical significance of measurement discrepancies was evaluated with respect to diagnosis of left ventricular hypertrophy (LVH), eligibility for disease-specific therapy, and prognosis. Statistical analysis included paired-sample t test, Cox proportional hazard models, Akaike information criterion (AIC), and intraclass correlation coefficients.
RESULTS: LVM indexed to body surface area (LVMI) and MWT were significantly higher at TTE compared with MRI (105 g/m2 ± 48 vs 78 g/m2 ± 36, P < .001 and 14 mm ± 4 vs 13 mm ± 5, P = .008, respectively). LVH classification was discordant between modalities in 23 patients (29%) (P < .001). Eligibility for disease-specific therapy based on MWT was discordant between modalities in 20 patients (26%) (P < .001). LVMI assessed with MRI was a better predictor of the combined endpoint compared with LVMI assessed with TTE (AIC, 127 vs 131). Interobserver agreement for LVMI and MWT was higher for MRI (intraclass correlation coefficient, 0.951 and 0.912, respectively) compared with TTE (intraclass correlation coefficient, 0.940 and 0.871; respectively).
CONCLUSION: TTE overestimates LVM and MWT and has lower reproducibility compared with cardiac MRI in Fabry disease. Measurement discrepancies between modalities are clinically significant with respect to diagnosis of LVH, prognosis, and treatment decisions.© RSNA, 2020. 2020 by the Radiological Society of North America, Inc.

Entities:  

Year:  2020        PMID: 33778580      PMCID: PMC7977989          DOI: 10.1148/ryct.2020190149

Source DB:  PubMed          Journal:  Radiol Cardiothorac Imaging        ISSN: 2638-6135


  33 in total

Review 1.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

2.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt
Journal:  J Am Soc Echocardiogr       Date:  2015-01       Impact factor: 5.251

3.  Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry Disease.

Authors:  Hassan Hazari; Israel Belenkie; Albert Kryski; James A White; Gavin Y Oudit; Richard Thompson; Tak Fung; Navdeep Dehar; Aneal Khan
Journal:  Can J Cardiol       Date:  2018-03-29       Impact factor: 5.223

4.  Comparison of Ventricular Septal Measurements in Hypertrophic Cardiomyopathy Patients Who Underwent Surgical Myectomy Using Multimodality Imaging and Implications for Diagnosis and Management.

Authors:  Dermot Phelan; Brett W Sperry; Paaladinesh Thavendiranathan; Patrick Collier; Zoran B Popović; Harry M Lever; Nicholas G Smedira; Milind Y Desai
Journal:  Am J Cardiol       Date:  2017-03-01       Impact factor: 2.778

Review 5.  The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease.

Authors:  Rebecca Perry; Ranjit Shah; Madiha Saiedi; Sanjana Patil; Anand Ganesan; Ales Linhart; Joseph B Selvanayagam
Journal:  JACC Cardiovasc Imaging       Date:  2019-07

6.  Discrepancies in Left Ventricular Mass Calculation Based on Echocardiography and Cardiovascular Magnetic Resonance Measurements in Patients with Left Ventricular Hypertrophy.

Authors:  Hee-Young Seo; Seung-Pyo Lee; Jun-Bean Park; Joo Myung Lee; Eun-Ah Park; Sung-A Chang; Hyung-Kwan Kim; Sung-Ji Park; Whal Lee; Yong-Jin Kim; Sang-Chol Lee; Seung Woo Park; Dae-Won Sohn; Yeon Hyeon Choe
Journal:  J Am Soc Echocardiogr       Date:  2015-07-17       Impact factor: 5.251

7.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Authors:  D A Hughes; P M Elliott; J Shah; J Zuckerman; G Coghlan; J Brookes; A B Mehta
Journal:  Heart       Date:  2007-05-04       Impact factor: 5.994

Review 8.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

9.  Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.

Authors:  Marieke Biegstraaten; Reynir Arngrímsson; Frederic Barbey; Lut Boks; Franco Cecchi; Patrick B Deegan; Ulla Feldt-Rasmussen; Tarekegn Geberhiwot; Dominique P Germain; Chris Hendriksz; Derralynn A Hughes; Ilkka Kantola; Nesrin Karabul; Christine Lavery; Gabor E Linthorst; Atul Mehta; Erica van de Mheen; João P Oliveira; Rossella Parini; Uma Ramaswami; Michael Rudnicki; Andreas Serra; Claudia Sommer; Gere Sunder-Plassmann; Einar Svarstad; Annelies Sweeb; Wim Terryn; Anna Tylki-Szymanska; Camilla Tøndel; Bojan Vujkovac; Frank Weidemann; Frits A Wijburg; Peter Woolfson; Carla E M Hollak
Journal:  Orphanet J Rare Dis       Date:  2015-03-27       Impact factor: 4.123

10.  Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort.

Authors:  Steffen E Petersen; Nay Aung; Mihir M Sanghvi; Filip Zemrak; Kenneth Fung; Jose Miguel Paiva; Jane M Francis; Mohammed Y Khanji; Elena Lukaschuk; Aaron M Lee; Valentina Carapella; Young Jin Kim; Paul Leeson; Stefan K Piechnik; Stefan Neubauer
Journal:  J Cardiovasc Magn Reson       Date:  2017-02-03       Impact factor: 5.364

View more
  1 in total

1.  Segmental strain analysis for the detection of chronic ischemic scars in non-contrast cardiac MRI cine images.

Authors:  M Polacin; M Karolyi; M Eberhard; A Gotschy; B Baessler; H Alkadhi; S Kozerke; R Manka
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.